These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 1566071)

  • 1. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin.
    Pil PM; Lippard SJ
    Science; 1992 Apr; 256(5054):234-7. PubMed ID: 1566071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repair of cisplatin--DNA adducts by the mammalian excision nuclease.
    Zamble DB; Mu D; Reardon JT; Sancar A; Lippard SJ
    Biochemistry; 1996 Aug; 35(31):10004-13. PubMed ID: 8756462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.
    Donahue BA; Augot M; Bellon SF; Treiber DK; Toney JH; Lippard SJ; Essigmann JM
    Biochemistry; 1990 Jun; 29(24):5872-80. PubMed ID: 2383564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
    Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins.
    Kaspárková J; Brabec V
    Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA.
    Jamieson ER; Lippard SJ
    Biochemistry; 2000 Jul; 39(29):8426-38. PubMed ID: 10913248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein.
    Imamura T; Izumi H; Nagatani G; Ise T; Nomoto M; Iwamoto Y; Kohno K
    J Biol Chem; 2001 Mar; 276(10):7534-40. PubMed ID: 11106654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
    Huang JC; Zamble DB; Reardon JT; Lippard SJ; Sancar A
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10394-8. PubMed ID: 7937961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
    Kane SA; Lippard SJ
    Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
    Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
    Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferential binding of high mobility group 1 protein to UV-damaged DNA. Role of the COOH-terminal domain.
    Pasheva EA; Pashev IG; Favre A
    J Biol Chem; 1998 Sep; 273(38):24730-6. PubMed ID: 9733773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.
    Cohen SM; Mikata Y; He Q; Lippard SJ
    Biochemistry; 2000 Sep; 39(38):11771-6. PubMed ID: 10995245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin.
    Bruhn SL; Pil PM; Essigmann JM; Housman DE; Lippard SJ
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2307-11. PubMed ID: 1372440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA.
    He Q; Ohndorf UM; Lippard SJ
    Biochemistry; 2000 Nov; 39(47):14426-35. PubMed ID: 11087395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA.
    Dunham SU; Lippard SJ
    Biochemistry; 1997 Sep; 36(38):11428-36. PubMed ID: 9298962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA.
    Yaneva J; Leuba SH; van Holde K; Zlatanova J
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13448-51. PubMed ID: 9391045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
    Takahara PM; Rosenzweig AC; Frederick CA; Lippard SJ
    Nature; 1995 Oct; 377(6550):649-52. PubMed ID: 7566180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells.
    Nagatani G; Nomoto M; Takano H; Ise T; Kato K; Imamura T; Izumi H; Makishima K; Kohno K
    Cancer Res; 2001 Feb; 61(4):1592-7. PubMed ID: 11245470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts.
    Hoffmann JS; Locker D; Villani G; Leng M
    J Mol Biol; 1997 Jul; 270(4):539-43. PubMed ID: 9245584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.